Despite significant advances in drug discovery technologies, many promising programs continue to fail due to limited translational relevance of preclinical models. Selecting experimental systems that faithfully reflect human disease biology — and integrating insights across in vitro and in vivo platforms — is essential for improving decision-making and reducing late-stage attrition.

In this webinar, we will present Cyagen’s comprehensive disease modelling ecosystem, spanning advanced cell-based assays, patient-relevant iPSC models, humanised rodent platforms, and gene therapy enablement services. Through practical examples and case studies, our experts will demonstrate how integrated, predictive models can generate actionable insights and support more confident progression from discovery to clinical development.

This webinar provides an overview of Cyagen’s end-to-end translational research platform designed to support drug discovery and development across multiple therapeutic areas. Attendees will learn how human-relevant in vitro systems, iPSC-derived disease models, and humanised rodent platforms can be strategically combined to strengthen target validation, efficacy assessment, and IND-enabling studies. Real-world examples will highlight how these integrated approaches help de-risk programs and accelerate development timelines.